



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 26, 2024

Rick Pauls  
President and Chief Executive Officer  
DiaMedica Therapeutics Inc.  
301 Carlson Parkway, Suite 210  
Minneapolis, MN 55305

**Re: DiaMedica Therapeutics Inc.  
Registration Statement on Form S-3  
Filed March 21, 2024  
File No. 333-278146**

Dear Rick Pauls:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jessica Dickerson at 202-551-8013 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Amy E. Culbert, Esq.